INTERNATIONAL SEARCH REPORT

International Application No PCT/EP2004/053604

A. CLASSIFICATION OF SUBJECT MATTER C12N15/11 A61K31/7125 A61K31/04 A61K31/7048 A61P35/00 C07K14/495 A61K31/166 A61K31/52 A61K38/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. RELDS SEARCHED

 $\begin{array}{ccc} \text{Minimum documentation searched} & \text{(classification system followed by classification symbols)} \\ & \text{C12N} & \text{A61K} & \text{A61P} \end{array}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

	lata base consulted during the international search (name of data	•			
EPU-In	ternal, WPI Data, PAJ, BIOSIS, EM	BASE			
	-				
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category °	Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to claim No.		
X	ARTEAGA C L ET AL: "REVERSAL RESISTANCE OF HUMAN BREAST CAR VIVO BY NEUTRALIZING ANTIBODIE TRANSFORMING GROWTH FACTOR-BET JOURNAL OF THE NATIONAL CANCER vol. 91, no. 1, 6 January 1999 (1999-01-06), p. XP000940473	CINOMAS IN S TO · A" INSTITUTE,	1,3,7-9, 11-16		
	ISSN: 0027-8874		1 17		
Y	the whole document		1-17		
Y	WO 94/25588 A (BIOGNOSTIK GES ULRICH (DE); BRYSCH WOLFGANG (I SCHLINGENS) 10 November 1994 (I cited in the application the whole document	DE);	1-17		
X Furth	er documents are listed in the continuation of box C.	X Patent family members are listed in	annex.		
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		"T" later document published after the international filing date or priority date and not in conflict with the application but clted to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family			
Date of the a	ctual completion of the international search	Date of mailing of the international search	h report		
3 August 2005		3 () 01 2006		
lame and m	ailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-200, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Andres, S			
	10 (second sheet) (January 2004)				

INT NATIONAL SEARCH REPORT

International Application No PCT/EP2004/053604

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT					
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
A	WOJTOWICZ-PRAGA SLAWOMIR: "Reversal of tumor-induced immunosuppression by TGF-beta inhibitors." INVESTIGATIONAL NEW DRUGS, vol. 21, no. 1, February 2003 (2003-02),		1-17		
-	pages 21-32, XP008035079 ISSN: 0167-6997 cited in the application the whole document				
Α .	YU D ET AL: "HYBRID OLIGONUCLEOTIDES: SYNTHESIS, BIOPHYSICAL PROPERTIES STABILITY STUDIES, AND BIOLOGICAL - ACTIVITY"				
	BIOORGANIC & MEDICINAL CHEMISTRY, vol. 4, no. 10, 1996, pages 1685-1692, XP000644792 ISSN: 0968-0896	•.			
A	RUBENSTEIN MARVIN ET AL: "Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol."				
	MEDICAL ONCOLOGY (TOTOWA), vol. 20, no. 1, 2003, pages 29-35, XP008035083 ISSN: 1357-0560 the whole document	•			
A	WO 99/63975 A (BIOGNOSTIK GES; BRYSCH WOLFGANG (DE); SCHLINGENSIEPEN KARL HERMANN (D) 16 December 1999 (1999-12-16) cited in the application				
A .	WO 01/68146 A (BIOGNOSTIK GES; SCHLINGENSIEPEN KARL HERMANN (DE); SCHLINGENSIEPEN RE) 20 September 2001 (2001-09-20) cited in the application	. •	_		
P,X	WO 2004/005552 A (MONIA BRETT P; DOBIE KENNETH W (US); FREIER SUSAN M (US); ISIS PHARMA) 15 January 2004 (2004-01-15) page 54 - page 55 page 79; example 5		1-3,5-16		
-	page 91 - page 100; examples 15,16				
·.					

International Application No PCT/EP2004/053604

Information on patent family members

Patent document cited in search report	Publication date		nt family nber(s)	Publication date
WO 9425588 A	10-11-1994		211762 T 235549 T	15-01-2002 15-04-2003
		AU 6	794594 A	21-11-1994
	•		429617 D1 429617 T2	14-02-2002 22-08-2002
		DE 69	432375 D1	30-04-2003
			432375 T2 555952 B2	12-02-2004 18-08-2004
•		JP 8	509370 T	08-10-1996
	·		600831 B2 924264 A	15-12-2004 29-01-2004
•			455689 B1	24-09-2002
WO 9963975 A	16-12-1999		274923 T	15-09-2004
-	·		154999 A 334960 A1	30-12-1999 16-12-1999
	•	DE 699	919869 D1	07-10-2004
			919869 T2 226414 T3	29-09-2005 16-03-2005
•			517434 T	18-06-2002
WO 0168146 A	20-09-2001		304858 T	15-10-2005
			010901 A 133988 A1	24-09-2001 19-09-2001
		JP 20035	526684 T	09-09-2003
		US 20031	186906 A1	02-10-2003
WO 2004005552 A	15-01-2004		281327 A1	23-01-2004
		US 20040	006030 A1	08-01-2004